RXST RxSight
- 52.980
- -0.590-1.10%
- 52.979
- -0.0010.00%
RxSight News
Here's Why We're Not At All Concerned With RxSight's (NASDAQ:RXST) Cash Burn Situation
Peeling Back The Layers: Exploring RxSight Through Analyst Insights
Needham Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $66
RxSight's Growth Trajectory: A Buy Recommendation on Strong Revenue Prospects and International Expansion
Three 'Buys,' Three 'Sells,' and a 'Hold,' by Oppenheimer Analysts
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
Companies Like RxSight (NASDAQ:RXST) Can Afford To Invest In Growth
RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences
RxSight Price Target Raised to $66.00/Share From $54.00 by Needham
RxSight Is Maintained at Buy by Needham
RxSight Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and RxSight (RXST)
Needham Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $66
Express News | Rxsight Inc : Needham Raises Target Price to $66 From $54
Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?
US$63.00: That's What Analysts Think RxSight, Inc. (NASDAQ:RXST) Is Worth After Its Latest Results
Deep Dive Into RxSight Stock: Analyst Perspectives (6 Ratings)
Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
Q2 2024 Rxsight Inc Earnings Call
Earnings Call: RxSight Sees Robust Growth With LAL Sales and Raised Guidance
Analysis
Price Target
No Data
No Data